ADHD and autism spectrum disorder (ASD) are both neurodevelopmental conditions, and they overlap far more than the diagnostic manuals historically acknowledged. Until 2013, the DSM-IV explicitly prohibited diagnosing both conditions in the same person - if someone met criteria for a pervasive developmental disorder, they could not receive an ADHD diagnosis. The DSM-5 removed that restriction, and the clinical picture has become much clearer as a result.
How Often They Co-Occur
A meta-analysis by Lai et al. (2019) found that 28% of individuals with ASD have comorbid ADHD. Going the other direction, ASD traits are elevated across many ADHD populations, though prevalence estimates vary depending on the sample. Clinical samples show higher co-occurrence rates than community samples, partly because people with both conditions tend to have greater functional impairment and are more likely to seek help.
The pre-DSM-5 prohibition almost certainly led to decades of underdiagnosis. Many individuals who had both conditions received only one label, with clinicians forced to pick whichever seemed more prominent at the time.
What They Share
Both ADHD and ASD involve difficulties with executive function - planning, cognitive flexibility, inhibitory control. Both conditions are associated with emotional regulation problems, motor coordination difficulties, sensory processing differences, and academic underperformance. On the surface, someone with ADHD who struggles to maintain friendships can look very similar to someone with ASD who has the same difficulty.
But the mechanisms behind these shared features often differ. In ADHD, social difficulties tend to stem from inattention and impulsivity - missing social cues because of distraction, interrupting conversations, or failing to follow the thread of group interactions. In ASD, social communication challenges are more fundamental, involving differences in theory of mind, pragmatic language use, and the ability to read nonverbal signals.
Similarly, both conditions involve sensory processing differences, but the patterns are distinct. ASD is more strongly associated with sensory hypersensitivity and restricted, repetitive behaviours. ADHD is driven more by dopaminergic and noradrenergic dysfunction producing inattention, hyperactivity, and impulsivity.
The Genetic Overlap
The shared genetics between ADHD and ASD represent one of the strongest findings in psychiatric genetics. Genome-wide association studies (GWAS) show a genetic correlation of r_g = 0.36 between the two conditions - meaning a substantial proportion of the genetic variants that increase risk for one condition also increase risk for the other.
Twin studies from Swedish registry data put this in sharper terms. Monozygotic co-twins of individuals with ASD have an odds ratio of 17.77 for also having ADHD, compared to 4.33 for dizygotic co-twins. Copy number variants (CNVs) associated with ADHD also contribute to ASD risk, and both sets of variants cluster in genes involved in ion channels, glutamate receptors, and central nervous system development.
Exome sequencing by Satterstrom et al. found that genes implicated by rare protein-truncating variants in ADHD are the same genes found in ASD. A Psychiatric Genomics Consortium cross-disorder analysis identified a shared "neurodevelopmental" factor that encompasses ADHD, ASD, and Tourette syndrome.
Neurobiological Overlap and Divergence
At the brain level, both conditions involve prefrontal cortex dysfunction, though the specific circuits differ. ADHD primarily involves dopaminergic system disruption in fronto-striatal networks. ASD involves more prominent serotonergic and glutamatergic system differences, though these neurotransmitter systems interact extensively.
White matter connectivity differences and cerebellar abnormalities are reported in both conditions. The overall picture is of two disorders with partially overlapping neural substrates - not the same condition with different labels, but not entirely separate entities either.
Diagnostic Challenges
Dual diagnosis creates specific clinical complications. The overlapping symptoms make it difficult to determine whether a given behaviour (say, difficulty sustaining attention in conversation) is driven by ADHD inattention, ASD social communication differences, or both. Careful assessment requires examining the developmental history, the consistency of symptoms across contexts, and the specific quality of the difficulties.
The combined presentation also tends to produce more severe impairment than either condition alone. Emotional dysregulation may be more intense when both conditions are present, and the social difficulties compound - ADHD impulsivity on top of ASD social communication differences creates a particularly challenging profile.
Treatment Considerations
Stimulant medications (methylphenidate and amphetamines) remain first-line treatment for ADHD symptoms, and current evidence suggests they are effective for ADHD symptoms even when ASD is present. However, there are caveats. Stimulants may be less effective in the combined ADHD+ASD presentation compared to ADHD alone, and side effects - particularly irritability and emotional reactivity - may be more pronounced.
Critically, there is little evidence that ADHD medications treat core ASD symptoms. Social communication difficulties, restricted interests, and sensory sensitivities are not meaningfully improved by stimulants. This means that treating the ADHD component addresses part of the picture, but behavioural interventions targeting ASD-specific challenges remain necessary.
Behavioural interventions for the combined presentation need to address both sets of symptoms. A parent training programme designed for ADHD alone may not account for the rigidity and sensory needs associated with ASD. An ASD-focused social skills group may not account for the impulsivity and inattention that come with ADHD.
Rethinking Diagnostic Categories
The ADHD-ASD overlap challenges the idea that diagnostic categories are natural kinds. As the shared genetic architecture makes clear, these are not two entirely separate disorders that happen to co-occur - they share common biological pathways, particularly those involving glutamate signalling and CNS development.
Some researchers have proposed a broader "neurodevelopmental continuum" rather than discrete disorders. The clinical categories are useful - they guide treatment decisions, facilitate communication between professionals, and help individuals understand their experiences. But they should not be reified. They are descriptions of symptom clusters, not fundamental divisions in how the brain can differ.
The ability to diagnose both conditions simultaneously, made possible by DSM-5 and ICD-11, is a pragmatic improvement. It means that individuals with both sets of difficulties can receive treatment targeted at each component, rather than having their less-prominent condition ignored.
References
- Lai, M.C. et al. (2019). Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. The Lancet Psychiatry, 6(10), 819-829.
- Satterstrom, F.K. et al. (2020). Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell, 180(3), 568-584.
- Sundquist, J. et al. (2015). ADHD and risk for drug use disorders. Acta Psychiatrica Scandinavica, 132(4), 315-325.
- Stanford, S.C. & Sciberras, E. (Eds.) (2022). New Discoveries in the Behavioral Neuroscience of ADHD. Springer.
- Cross-Disorder Group of the Psychiatric Genomics Consortium (2019). Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell, 179(7), 1469-1482.